日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Landscape of splicing factors in early-onset gastric cancer reveals SRSF1 as a key driver of oxaliplatin resistance

早期胃癌中剪接因子的图谱揭示SRSF1是奥沙利铂耐药性的关键驱动因素

Zhong, Bin; Xiong, Zhizhong; Xu, Haoyang; Zheng, Jiabo; Mohamed, Saddam Ahmed; Sun, Jiachen; Huang, Dayin; Deng, Zijian; Guo, Jianping; Peng, Junsheng; Chen, Yonghe; Lian, Lei

SRSF1 as a promising biomarker and key player in the pathogenesis of Alzheimer's disease

SRSF1作为一种有前景的生物标志物和阿尔茨海默病发病机制中的关键因素

Liu, Yanchen; Zhao, Yi; Yao, Yanting; Liu, Dan; Sun, Yilei; Xu, Weishi; Yu, Hongli; Chi, Lijun

Dysregulation of SRSF11 in Cancer: Mechanistic Insights and Biomarker Potential for Diagnosis and Therapy

癌症中SRSF11的失调:机制解析及其作为诊断和治疗生物标志物的潜力

Jun, Yang; Shanshan, Liu; Jingwen, Xiao; Yu, He; Jianlong, Xiao; Qingfeng, Shi

Exosomal miR-2110 from PM2.5-Exposed Lung Epithelial Cells Targets SRSF1 to Promote M1 Macrophage Polarization and Inflammatory Responses in COPD.

PM2.5暴露的肺上皮细胞的外泌体miR-2110靶向SRSF1,促进COPD中M1巨噬细胞极化和炎症反应。

Miao Yehong, Gu Jianjun, Li Juan, Sheng Danye

SRSF1 haploinsufficiency drives the neurodevelopmental phenotype of the 17q22 deletion syndrome

SRSF1单倍体不足是17q22缺失综合征神经发育表型的驱动因素。

Wu, Youlan; Gao, Chuanfen; Chen, Zhenghe; Liu, Fang; Yuan, Jing; Cheng, Weisheng

RBM15 Mediated m6A Modification of SRSF1 Inhibits Cuproptosis in Non-Small Cell Lung Cancer by Mediating ATP7B Alternative Splicing

RBM15介导的SRSF1 m6A修饰通过介导ATP7B选择性剪接抑制非小细胞肺癌中的铜凋亡

Shan-Shan Mao,Dong-Yu Wu,Rong-Hua Cui,Xiao-Zhen Cheng

SRSF1 regulates polyadenylation site selection independently of and through coordination with U1 snRNP

SRSF1通过与U1 snRNP协同作用,独立于U1 snRNP调控多聚腺苷酸化位点的选择。

Merens, Hope E; Raicu, Ana-Maria; Carroll, Christine L; Kourkoulakos, Mike; Fiszbein, Ana; Churchman, L Stirling

KAT2A-driven succinylation of SRSF11 enforces spliceosome-mediated RAD52 splicing to promote homologous recombination and radioresistance in hepatocellular carcinoma

KAT2A驱动的SRSF11琥珀酰化增强剪接体介导的RAD52剪接,从而促进肝细胞癌中的同源重组和放射抗性。

Wu, Jun; Yuan, Jingsheng; Liu, Zijian; Zhou, Yongjie; Zhang, Bo; Xu, Yahong; Zeng, Qiwen; Wu, Zhenru; Kong, Lingxiang; Wang, Jiaguo; Zhang, Bohan; Yang, Jian; Lv, Tao; Shi, Yujun; Yang, Jiayin

Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells

靶向SRSF1可通过双重作用于CD8+T细胞和肿瘤细胞来增强癌症免疫疗法。

Gui-Qi Zhu # ,Zheng Tang # ,Tian-Hao Chu # ,Biao Wang # ,Shi-Ping Chen ,Chen-Yang Tao ,Jia-Liang Cai ,Rui Yang ,Wei-Feng Qu ,Yi Wang ,Qian-Fu Zhao ,Run Huang ,Meng-Xin Tian ,Yuan Fang ,Jun Gao ,Xiao-Ling Wu ,Jian Zhou ,Wei-Ren Liu ,Zhi Dai ,Ying-Hong Shi ,Jia Fan

Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification

靶向 O-GlcNAc 修饰的 METTL3 可通过减少 SRSF1 m6A 修饰来抑制 MDS/AML 的进展。

Junjie Gou,Yi Wang,Jingjing Feng,Kaijing Chang,Kexin Wang,Jingjing Bi,Junqi Ge,Chongfu Zhao,Songdi Wu,Zengqi Tan,Feng Guan,Xiang Li